The investment enhances Lonza’s capabilities and flexibility to support both clinical and commercial supply and will play a key role in meeting the growing market demand for bioconjugates
Through the new agreements, Cristal Therapeutics and McSAF will gain access to Lonza’s integrated bioconjugates offering and will be able to leverage Lonza’s expertise in developing and manufacturing bioconjugates
The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
The current ruling will assure the safety of the use of Ranitidine for Indian patients
Shilpa Medicare Ltd's finished dosage form manufacturing facility, Unit IV, situated at Pharma SEZ, Jadcherla, Telangana has received Health Canada GMP approval
To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan
Collaboration to implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox
The core of “LANXESS Biosecurity Solutions” is a portfolio of scientifically formulated, highly effective and versatile biocidal products
Through the collaboration, Lonza will gain access to Singzyme’s enzymatic conjugation platform enabling the site-specific binding of payloads with peptidic linkers to proteins of interest
Subscribe To Our Newsletter & Stay Updated
